Trials / Completed
CompletedNCT00539669
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer. Assess the progression free survival, tolerance, duration of response and survival in the same patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel |
Timeline
- Start date
- 2003-03-01
- First posted
- 2007-10-04
- Last updated
- 2007-10-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00539669. Inclusion in this directory is not an endorsement.